Ticker > Company >

Anuh Pharma share price

Anuh Pharma Ltd.

  51.29 K   174   29 NSE: ANUHPHR BSE: 506260 SECTOR: Pharmaceuticals & Drugs

83.85
+4.95 (6.27%)
BSE: Today, 02:57 PM

Price Summary

Today's High

₹ 84.01

Today's Low

₹ 78.32

52 Week High

₹ 93

52 Week Low

₹ 66.72

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

840.38 Cr.

Enterprise Value

832.08 Cr.

No. of Shares

10.02 Cr.

P/E

19.03

P/B

2.31

Face Value

₹ 5

Div. Yield

1.85 %

Book Value (TTM)

₹  36.28

CASH

8.3 Cr.

DEBT

0 Cr.

Promoter Holding

71.8 %

EPS (TTM)

₹  4.41

Sales Growth

16.65%

ROE

12.1 %

ROCE

16.02%

Profit Growth

-13.32 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year16.65%
3 Year13.52%
5 Year12.3%

Profit Growth

1 Year-13.32%
3 Year4.3%
5 Year7.62%

ROE%

1 Year12.1%
3 Year16.67%
5 Year16.2%

ROCE %

1 Year16.02%
3 Year21.82%
5 Year21.17%

Debt/Equity

0

Price to Cash Flow

-279.05

Interest Cover Ratio

57.7763

CFO/PAT (5 Yr. Avg.)

0.603186205717196

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2026 71.80 0.00
Mar 2026 71.80 0.00
Dec 2025 71.82 0.00
Sep 2025 71.82 0.00
Jun 2025 69.92 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 10.4981 Cr.
  • Company has been maintaining healthy ROCE of 21.818% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 57.7763.
  • The company has an efficient Cash Conversion Cycle of 53.075 days.
  • Company has a healthy liquidity position with current ratio of 2.2232.
  • The company has a high promoter holding of 71.8%.

 Limitations

  • The company has shown a poor profit growth of 4.29641468532551% for the Past 3 years.
  • The company has shown a poor revenue growth of 13.5195459077633% for the Past 3 years.
  • Company has negative cash flow from operations of -3.0116.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 186.48 185.88 197.18 202.12 193.81
Total Expenditure 176.19 174 180.38 182.23 177.52
Operating Profit 10.29 11.88 16.8 19.88 16.29
Other Income 3.39 0.98 4.11 -1.26 3.08
Interest 0.21 0.08 0.08 0.11 0
Depreciation 2.52 2.86 3 3 2.43
Exceptional Items 0 0 0 0 0
Profit Before Tax 10.95 9.92 17.83 15.52 16.93
Tax 2.65 2.31 4.38 3.84 5.5
Profit After Tax 8.3 7.61 13.45 11.68 11.43
Adjusted EPS (Rs) 0.83 0.76 1.34 1.17 1.14

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Net Sales 486.65 527.49 647 661.51 771.66
Total Expenditure 439.18 475.68 571.25 599.98 714.22
Operating Profit 47.46 51.8 75.75 61.53 57.44
Other Income 5.2 6.11 12.1 9.46 9.12
Interest 1.58 0.75 0.96 1.24 0.96
Depreciation 11.96 9.7 8.58 8.74 11.38
Exceptional Items 0 0 0 0 0
Profit Before Tax 39.12 47.47 78.31 61.01 54.22
Tax 8.56 11.29 18.25 13.65 13.18
Net Profit 30.56 36.18 60.06 47.35 41.05
Adjusted EPS (Rs.) 3.05 3.61 5.99 4.72 4.1

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity and Liabilities
Share Capital 25.06 25.06 25.06 25.06 50.11
Total Reserves 188.72 216.17 266.16 300.97 302.11
Borrowings 0 0 0 0 0
Other N/C liabilities 2.5 1.66 1.35 0.01 -1.72
Current liabilities 130.91 161.34 152.69 178.51 203
Total Liabilities 347.17 404.21 445.26 504.55 553.51
Assets
Net Block 61.42 52.81 48.95 58.21 56.62
Capital WIP 0.1 0 0.45 0.27 0
Intangible WIP 0 0 0 0 0
Investments 21.21 39.68 41.71 51.95 39.58
Loans & Advances 2.2 4.11 1.31 2.64 0.69
Other N/C Assets 3.55 0 14.3 15.3 5.3
Current Assets 258.69 307.61 338.54 376.17 451.32
Total Assets 347.17 404.21 445.26 504.55 553.51
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Profit from operations 39.12 47.47 78.31 61.01 54.22
Adjustment 8.17 3.53 -2.73 0.33 10.92
Changes in Assets & Liabilities -9.29 16.37 -43.58 -13.09 -54.91
Tax Paid -9.14 -13.47 -19.07 -11.12 -13.24
Operating Cash Flow 28.86 53.9 12.93 37.12 -3.01
Investing Cash Flow -7.82 -43.48 0.92 -19.91 17.84
Financing Cash Flow -19.45 -12.29 -8.57 -4.86 -26.33
Net Cash Flow 1.6 -1.87 5.27 12.36 -11.5

Corporate Actions

Investors Details

PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
promoters 69.92 71.82 71.82 71.80 71.80
aruna navnit shah 0.01 0.01 0.01 0.01 0.01
bharat nemchand shah 3.73 3.73 3.73 3.73 3.73
bharti bipin shah 19.43 19.43 19.43 19.43 19.43
bipin nemchand shah - 6.21 14.69 14.69 14.69
damyanti n shah 0.06 0.06 0.06 0.06 0.06
dhanishta ritesh shah - 0.36 0.36 0.36 0.36
dina satish shah 2.22 2.22 2.22 2.22 2.22
gaurav satish shah 3.19 3.19 3.19 3.19 3.19
harshit bharat shah 0.50 0.50 0.50 0.50 0.50
hemant babubhai choksi 0.02 0.02 0.02 0.02 0.02
hemruchi vivek shah - 0.36 0.36 0.36 0.36
indu kishor mody 0.03 0.03 0.03 0.01 0.01
japosha trading llp 0.19 0.19 0.19 0.19 0.19
jasmine samir shah - 0.66 0.66 0.66 0.66
ketan lalit shah 0.48 0.48 0.48 0.48 0.48
kinjal siddharth jhaveri 0.81 0.81 0.81 0.81 0.81
kiran piyush shah 0.02 0.02 0.02 0.02 0.02
madhurika narendra shah 0.01 0.01 0.01 0.01 0.01
mahesh kantilal shah 0.17 0.17 0.17 0.17 0.17
mrudula jayantilal shah 2.33 2.33 2.33 2.33 2.33
mrudula praful shah 0.12 0.12 0.12 0.12 0.12
mukesh kantilal shah 0.01 0.01 0.01 0.01 0.01
neeta ketan shah - 0.52 0.52 0.52 0.52
nina vijay shah 0.06 0.06 0.06 0.06 0.06
panna mahesh shah 0.20 0.20 0.20 0.20 0.20
praful kantilal shah 0.46 0.46 0.46 0.46 0.46
prafulla lalit shah 14.47 14.47 14.47 14.47 14.47
ritesh bipin shah - 2.31 2.31 2.31 2.31
rohan mahesh shah 0.08 0.08 0.08 0.08 0.08
samir jayantilal shah 1.72 1.72 1.72 1.72 1.72
surekha bharat shah 0.27 0.27 0.27 0.27 0.27
urvashi manoj sanghavi 0.01 0.01 0.01 0.01 0.01
vivek bipin shah - 2.33 2.33 2.33 2.33
bipin nemchand shah (huf)... - 8.48 - - -
bipin nemchand shah 6.21 - - - -
bipin nemchand shah (hu... 8.48 - - - -
ritesh bipin shah 2.31 - - - -
vivek bipin shah 2.33 - - - -
PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
investors 30.08 28.18 28.18 28.20 28.20
investor education and pr... - - 0.11 0.13 0.13
michael dsouza - - 1.06 1.09 1.10
investor education and pr... 0.11 0.11 - - -

Annual Reports

Title Link
Title Link
Annual Report 2026
Annual Report 2024
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit ICRA
Credit ICRA
Credit ICRA
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY22
Concall Q3FY22
Concall Q3FY21
Concall Q2FY22
Concall Q1FY22
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY23
Presentation Q4FY21
Presentation Q4FY20
Presentation Q3FY24
Presentation Q3FY23
Presentation Q3FY22
Presentation Q3FY21
Presentation Q2FY22
Presentation Q2FY21
Presentation Q1FY27
Presentation Q1FY22
Presentation Q1FY21

Company News

Anuh Pharma - Quaterly Results 8 Aug, 12:00 AM Anuh Pharma informs about newspaper publication 22 May, 5:02 PM Anuh Pharma informs about press release 28 Apr, 6:12 PM USFDA completes inspection at Anuh Pharma’s Palghar facilities 7 Feb, 2:32 PM Anuh Pharma - Quaterly Results 7 Feb, 12:00 AM Anuh Pharma informs about updates 5 Dec, 4:28 PM Anuh Pharma surges on getting CEP for Sulfadimethoxine from EDQM 5 Dec, 3:23 PM Anuh Pharma gets CEP for Sulfadimethoxine from EDQM 5 Dec, 3:12 PM Anuh Pharma - Quaterly Results 8 Nov, 12:00 AM Anuh Pharma informs about confirmation certificate 10 Oct, 5:38 PM Anuh Pharma informs about press release 9 Sep, 4:36 PM Anuh Pharma informs about investor presentation 22 Aug, 2:53 PM Anuh Pharma - Quaterly Results 8 Aug, 5:13 PM Anuh Pharma - Quaterly Results 8 Aug, 5:13 PM Anuh Pharma - Quaterly Results 8 Aug, 5:13 PM Anuh Pharma informs about allotment of bonus equity shares 16 Jul, 3:39 PM Anuh Pharma - Quaterly Results 23 May, 9:10 PM Anuh Pharma - Quaterly Results 23 May, 9:10 PM Anuh Pharma - Quaterly Results 7 Feb, 6:01 PM Anuh Pharma - Quaterly Results 7 Feb, 6:01 PM Anuh Pharma informs about credit rating 4 Jan, 3:55 PM Anuh Pharma - Quaterly Results 8 Nov, 4:56 PM Anuh Pharma - Quaterly Results 8 Nov, 4:56 PM Anuh Pharma informs about disclosure 3 Sep, 12:58 PM Anuh Pharma informs about change in directorate 22 Aug, 2:26 PM Anuh Pharma - Quaterly Results 9 Aug, 6:06 PM Anuh Pharma - Quaterly Results 9 Aug, 6:06 PM Anuh Pharma - Quaterly Results 9 Aug, 6:06 PM Anuh Pharma informs about confirmation certificate 10 Jul, 5:16 PM Anuh Pharma informs about closure of trading window 24 Jun, 4:19 PM Anuh Pharma informs about newspaper publications 18 May, 3:09 PM Anuh Pharma - Quaterly Results 17 May, 6:59 PM Anuh Pharma - Quaterly Results 17 May, 6:59 PM Anuh Pharma informs about board meeting 9 May, 5:20 PM Anuh Pharma informs about change in directorate 1 Apr, 3:04 PM Anuh Pharma informs about update 28 Feb, 12:58 PM Anuh Pharma submits investor presentation 19 Feb, 2:54 PM Anuh Pharma - Quaterly Results 9 Feb, 4:32 PM Anuh Pharma - Quaterly Results 9 Feb, 4:32 PM Anuh Pharma - Quaterly Results 9 Feb, 4:32 PM Anuh Pharma informs about proceedings of AGM 19 Aug, 3:12 PM Anuh Pharma - Quaterly Results 11 Aug, 4:31 PM Anuh Pharma - Quaterly Results 11 Aug, 4:31 PM Anuh Pharma informs about AGM 25 Jul, 12:46 PM Anuh Pharma - Quaterly Results 19 May, 4:28 PM Anuh Pharma - Quaterly Results 19 May, 4:28 PM Anuh Pharma informs about certificate 4 May, 1:05 PM Anuh Pharma - Quaterly Results 10 Feb, 4:48 PM Anuh Pharma - Quaterly Results 10 Feb, 4:48 PM Anuh Pharma informs about confirmation certificate 12 Jan, 5:39 PM

Anuh Pharma Stock Price Analysis and Quick Research Report. Is Anuh Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Anuh Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Anuh Pharma has a PE ratio of 18.7579415501906 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Anuh Pharma has ROA of 7.7588% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Anuh Pharma has a Current ratio of 2.2232.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Anuh Pharma has a ROE of 12.1036%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Anuh Pharma has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Anuh Pharma has reported revenue growth of 16.65% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Anuh Pharma for the current financial year is 7.44358830745355%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Anuh Pharma is Rs 1.5 and the yield is 1.845%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Anuh Pharma is Rs 4.4072. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Anuh Pharma in Ticker for free. Also, one can get the intrinsic value of Anuh Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Anuh Pharma FAQs

Q1. What is Anuh Pharma share price today?
Ans: The current share price of Anuh Pharma is Rs 82.67.

Q2. What is the market capitalisation of Anuh Pharma?
Ans: Anuh Pharma has a market capitalisation of Rs 828.551808 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Anuh Pharma?
Ans: The PE ratio of Anuh Pharma is 18.7579415501906 and the P/B ratio of Anuh Pharma is 2.27843984610127, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Anuh Pharma share?
Ans: The 52-week high share price of Anuh Pharma is Rs 93, and the 52-week low share price of Anuh Pharma is Rs 67.

Q5. Does Anuh Pharma pay dividends?
Ans: Currently, Anuh Pharma pays dividends. Dividend yield of Anuh Pharma is around 1.845%.

Q6. What are the face value and book value of Anuh Pharma shares?
Ans: The face value of Anuh Pharma shares is Rs 5, while the book value per share of Anuh Pharma is around Rs 36.2836. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Anuh Pharma?
Ans: Anuh Pharma has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Anuh Pharma?
Ans: The ROE of Anuh Pharma is 12.1036% and ROCE of Anuh Pharma is 16.0223%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Anuh Pharma a good buy for the long term?
Ans: The Anuh Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Anuh Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Anuh Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Anuh Pharma’s financials?
Ans: You can review Anuh Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Anuh Pharma
X